SYRE — Spyre Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Spyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -65.8 | -83.8 | -339 | -208 | -155 |
| Depreciation | |||||
| Non-Cash Items | 8.68 | 7.61 | 243 | 55.1 | -8.12 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.83 | -5.5 | -5.21 | -4.53 | -5.93 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -53.7 | -80.1 | -99.9 | -157 | -169 |
| Capital Expenditures | -0.573 | -0.038 | 0 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -22 | 57 | -108 | -353 | -143 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -22.6 | 57 | -108 | -353 | -143 |
| Financing Cash Flow Items | — | — | -5.79 | -1.84 | -5.41 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.39 | 42.7 | 361 | 411 | 309 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -75 | 19.4 | 153 | -99.8 | -3.7 |